Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial.

K Ranh Voong,Lincy S Lal,Deborah A Kuban,Thomas J Pugh,J Michael Swint,Joy Godby,Seungtaek Choi,Andrew K Lee,Pamela J Schlembach,Steven J Frank,Sean E McGuire,Karen E Hoffman

Advances in Radiation Oncology（2017）

引用 21|浏览22

暂无评分

摘要

HIMRT is more cost-efficient than CIMRT for treating prostate cancer, even when taking into account the costs related to late radiation toxicities. HIMRT enhances the value of prostate radiation when compared with CIMRT.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要